James William Kupiec, Chief Clinical Development Officer at CASSAVA SCIENCES INC (SAVA), bought 2,500 shares at $24.44 ($61K) on 2022-08-23, disclosed to the SEC on 2022-08-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.